Diabetes Care, Vol 21, Issue 10 1726-1731, Copyright © 1998 by American Diabetes Association

ARTICLES

Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes

BL Brunelle, J Llewelyn, JH Anderson, EA Gale and VA Koivisto
Lilly Research Laboratories, Indianapolis, Indiana, USA.

OBJECTIVE: A precise time-action profile of insulin lispro (Humalog) at mealtime may reduce the incidence of severe hypoglycemia. Because it is a rare complication, we performed a cumulative meta-analysis to compare the frequency of severe hypoglycemia during insulin lispro and human regular insulin therapy in type 1 diabetic patients. RESEARCH DESIGN AND METHODS: The analysis included eight large multi-center clinical trials, three with parallel and five with crossover designs. The studies included 2,576 type 1 diabetic patients in total, with 2,327 receiving insulin lispro and 2,339 receiving regular human insulin, representing > 1,400 patient-years of insulin therapy Severe hypoglycemia was defined as coma or requiring glucagon or intravenous glucose. The patients received either NPH or ultralente as their basal insulin and insulin lispro or regular human insulin before each meal. RESULTS: Seventy-two patients (3.1%) had a total of 102 severe hypoglycemic episodes during insulin lispro therapy compared with 102 patients (4.4%) with a total of 131 episodes during regular human insulin therapy (P=0.024). CONCLUSIONS: The results of this meta-analysis demonstrate that in type 1 diabetic patients, the frequency of severe hypoglycemia can be reduced by taking insulin lispro as compared with regular human insulin therapy.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Shalitin and M. Phillip Hypoglycemia in Type 1 Diabetes: A still unresolved problem in the era of insulin analogs and pump therapy Diabetes Care, February 1, 2008; 31(Supplement_2): S121 - S124. [Abstract] [Full Text] [PDF]

				I. B. Hirsch Insulin Analogues N. Engl. J. Med., January 13, 2005; 352(2): 174 - 183. [Full Text] [PDF]

				M. K. Bulsara, C. D. J. Holman, E. A. Davis, and T. W. Jones The Impact of a Decade of Changing Treatment on Rates of Severe Hypoglycemia in a Population-Based Cohort of Children With Type 1 Diabetes Diabetes Care, October 1, 2004; 27(10): 2293 - 2298. [Abstract] [Full Text] [PDF]

				I. W Gallen Review: Helping the athlete with type 1 diabetes The British Journal of Diabetes & Vascular Disease, March 1, 2004; 4(2): 87 - 92. [Abstract] [PDF]

				K. K. Daugherty Review of Insulin Therapy Journal of Pharmacy Practice, February 1, 2004; 17(1): 10 - 19. [Abstract] [PDF]

				B. Ahmad Review: Pharmacology of insulin The British Journal of Diabetes & Vascular Disease, January 1, 2004; 4(1): 10 - 14. [Abstract] [PDF]

				N. Weintrob, H. Benzaquen, A. Galatzer, S. Shalitin, L. Lazar, G. Fayman, P. Lilos, Z. Dickerman, and M. Phillip Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injection Regimens in Children With Type 1 Diabetes: A Randomized Open Crossover Trial Pediatrics, September 1, 2003; 112(3): 559 - 564. [Abstract] [Full Text] [PDF]

				P. E. Cryer, S. N. Davis, and H. Shamoon Hypoglycemia in Diabetes Diabetes Care, June 1, 2003; 26(6): 1902 - 1912. [Abstract] [Full Text] [PDF]

				D. E. DeWitt and I. B. Hirsch Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review JAMA, May 7, 2003; 289(17): 2254 - 2264. [Abstract] [Full Text] [PDF]

				R. Boskovic, D. S. Feig, L. Derewlany, B. Knie, G. Portnoi, and G. Koren Transfer of Insulin Lispro Across the Human Placenta: In vitro perfusion studies Diabetes Care, May 1, 2003; 26(5): 1390 - 1394. [Abstract] [Full Text] [PDF]

				D. R Elbourne, D. G Altman, J. P. Higgins, F. Curtin, H. V Worthington, and A. Vail Meta-analyses involving cross-over trials: methodological issues Int. J. Epidemiol., February 1, 2002; 31(1): 140 - 149. [Abstract] [Full Text] [PDF]

				P. E. Cryer and B. P. Childs Negotiating the Barrier of Hypoglycemia in Diabetes Diabetes Spectr, January 1, 2002; 15(1): 20 - 27. [Abstract] [Full Text] [PDF]

				L. C. Deeb, J. H. Holcombe, R. Brunelle, S. Zalani, S. Brink, M. Jenner, H. Kitson, K. Perlman, and M. Spencer Insulin Lispro Lowers Postprandial Glucose in Prepubertal Children With Diabetes Pediatrics, November 1, 2001; 108(5): 1175 - 1179. [Abstract] [Full Text] [PDF]

				Z. Vajo, J. Fawcett, and W. C. Duckworth Recombinant DNA Technology in the Treatment of Diabetes: Insulin Analogs Endocr. Rev., October 1, 2001; 22(5): 706 - 717. [Abstract] [Full Text] [PDF]

				A. Bhattacharyya, S. Brown, S. Hughes, and P.A. Vice Insulin lispro and regular insulin in pregnancy QJM, May 1, 2001; 94(5): 255 - 260. [Abstract] [Full Text] [PDF]

				R. Rabasa-Lhoret, J. Bourque, F. Ducros, and J.-L. Chiasson Guidelines for Premeal Insulin Dose Reduction for Postprandial Exercise of Different Intensities and Durations in Type 1 Diabetic Subjects Treated Intensively With a Basal-Bolus Insulin Regimen (Ultralente-Lispro) Diabetes Care, April 1, 2001; 24(4): 625 - 630. [Abstract] [Full Text]

				Z. Vajo and W. C. Duckworth Genetically Engineered Insulin Analogs: Diabetes in the New Millenium Pharmacol. Rev., March 1, 2000; 52(1): 1 - 10. [Abstract] [Full Text] [PDF]

				M. Berger and I. Muhlhauser Diabetes Care and Patient-Oriented Outcomes JAMA, May 12, 1999; 281(18): 1676 - 1678. [Full Text] [PDF]